



Tetralogy of Fallot and Pulmonary Hypertension

Alexandra A Frogoudaki

Congenital Heart Disease Clinic
Second Cardiology Department
ATTIKON University Hospital



- Female 52y
- Tetralogy of Fallot
- Secundum atrial septal defect
- Interventions

Right BT shunt at age 3

Surgical correction TOF at age 6




Tetralogy of Fallot

Most common cyanotic congenital heart disease

- Valvular and subvalvular pulmonary stenosis
- Ventricular septal defect
- Aorta overriding the septum
- Right ventricular hypertrophy



Anterior malalignment
of the septum





Surgical Treatment

- 1944: Blalock Taussig shunt
- 1948: Brock procedure (resection of the stenosed infundibulum with a punch)
- 1954: First total repair by C Walton Lillehei





Clinical


- Atrial fibrillation
- History of hemoptysis 1/2019
- NYHA III

On examination

- Cyanotic SAT 75%
- BP 110/60mmHg, HR 100/min
- Diastolic murmur left parasternal edge
- Mild peripheral oedema



ECG







Hematology-Biochemistry

- Ht 47% MCV 66
- Bilirubin 2.3 mg/dl (direct 0.5mg/dl)>1.7 mg/dl
- NTproBNP 6131pg/ml
- Normal kidney function
- TSH 5.03 μ UI/ml
- Slightly elevated AST


10/04/2019 13:49:25
ACE
f: 1.7 MHz/3.3 MHz
P: 0 dB



20/03/2019 11:26:46
ACE
f: 2.2 MHz
P: 0 dB




3.36 m/s
45.17 mmHg
8.28 kHz



RV SP 55-60mmHg

1.9 cm






Sharp

88
HR

+

v 0.09 m/s


p 0.03 mmHg





20/03/2019 11:27:50
ACE
f: 2.2 MHz
P: 0 dB

Sharp
.63
-.63




117
1:42HR

10/04/2019 13:59:21
f: 5.0 MHz
P: -1 dB





10/04/2019 13:57:38
f: 3.6 MHz
P: -1 dB



59
3:15HR


10/04/2019 14:01:42
f: 3.6 MHz
P: -1 dB





10/04/2019 14:05:09
f: 5.0 MHz
P: -1 dB




10/04/2019 14:05:01
f: 3.6 MHz
P: -1 dB



10/04/2019 14:05:01
f: 3.6 MHz
P: -1 dB



10/04/2019 14:05:01
f: 3.6 MHz
P: -1 dB






1 cm
HR 99

10/04/2019 14:09:46
f: 5.0 MHz
P: -1 dB

10/04/2019 14:10:26
f: 3.6 MHz
P: -1 dB

10/04/2019 14:10:26
f: 3.6 MHz
P: -1 dB

2 L 0.9 cm
1 L 2.6 cm




101
HR



CTPA





- No signs of pulmonary embolism
- Main and left PA dilation up to 4cm
- Small right PA
- Small pleural effusion





MRI

- LV EF 45%
- RV EF 25%
- Severe pulmonary regurgitation (RF 40%)
- Dilated main and left PA
- Small right PA (RPA: LPA 23%:77%)
- Small RA thrombus













En face flow map



Large ASD
Bidirectional
flow








Early Gd

Late Gd





Work-up

- Abdomen U/S
- Connective tissue diseases work-up
- 24 hour Holter monitoring



Treatment

- Iron intravenously
- Digoxin
- B Blocker
- Eplerenone
- Furosemide
- Coumadin



What is the cause of pulmonary hypertension?

- Segmental pulmonary hypertension?
- Atrial septal defect?
- Post capillary pulmonary hypertension?



Management?

- Reduce the RV volume overload
- Targeted PAH therapy
- Medical treatment



Haemodynamic definitions and updated clinical classification of pulmonary hypertension

G rard Simonneau^{1,2}, David Montani ^{1,2}, David S. Celermajer³,
Christopher P. Denton⁴, Michael A. Gatzoulis⁵, Michael Krowka⁶,
Paul G. Williams⁷ and Rogerio Souza ⁸

Number 4 in the series

“Proceedings of the 6th World Symposium on Pulmonary Hypertension”

Edited by N. Gali , V.V. McLaughlin, L.J. Rubin and G. Simonneau

TABLE 1 Haemodynamic definitions of pulmonary hypertension (PH)

Definitions	Characteristics	Clinical groups [#]
Pre-capillary PH	mPAP >20 mmHg PAWP ≤15 mmHg PVR ≥3 WU	1, 3, 4 and 5
Isolated post-capillary PH (IpcPH)	mPAP >20 mmHg PAWP >15 mmHg PVR <3 WU	2 and 5
Combined pre- and post-capillary PH (CpcPH)	mPAP >20 mmHg PAWP >15 mmHg PVR ≥3 WU	2 and 5



Pulmonary Hypertension associated with Congenital Heart Disease

1. Eisenmenger's syndrome

Includes all large intra- and extra-cardiac defects which begin as systemic-to-pulmonary shunts and progress with time to severe elevation of PVR and to reversal (pulmonary-to-systemic) or bidirectional shunting; cyanosis, secondary erythrocytosis, and multiple organ involvement are usually present.

2. PAH associated with prevalent systemic-to-pulmonary shunts

- Correctable^a
- Non-correctable

Includes moderate to large defects; PVR is mildly to moderately increased, systemic-to-pulmonary shunting is still prevalent, whereas cyanosis at rest is not a feature.

3. PAH with small/coincidental defects^b

Marked elevation in PVR in the presence of small cardiac defects (usually ventricular septal defects <1 cm and atrial septal defects <2 cm of effective diameter assessed by echo), which themselves do not account for the development of elevated PVR; the clinical picture is very similar to idiopathic PAH. Closing the defects is contra-indicated.

4. PAH after defect correction

Congenital heart disease is repaired, but PAH either persists immediately after correction or recurs/develops months or years after correction in the absence of significant postoperative haemodynamic lesions.



GROUP 5



TABLE 7 Pulmonary hypertension with unclear and/or multifactorial mechanisms

5.1 Haematological disorders	Chronic haemolytic anaemia Myeloproliferative disorders
5.2 Systemic and metabolic disorders	Pulmonary Langerhans cell histiocytosis Gaucher disease Glycogen storage disease Neurofibromatosis Sarcoidosis
5.3 Others	Chronic renal failure with or without haemodialysis Fibrosing mediastinitis
5.4 Complex congenital heart disease	See the Task Force article by ROSENZWEIG <i>et al.</i> [31] in this issue of the <i>European Respiratory Journal</i>

Galie et al Eur J Respir 2019

TABLE 5 Complex congenital heart disease (group 5.4)

Segmental pulmonary hypertension

Isolated pulmonary artery of ductal origin

Absent pulmonary artery

Pulmonary atresia with ventricular septal defect and major aorto-pulmonary collateral arteries

Hemitruncus

Other

Single ventricle

Unoperated

Operated

Scimitar syndrome


Rosenweig et al EurJ Respir 2019



Definition and Management of Segmental Pulmonary Hypertension



Konstantinos Dimopoulos, MD, MSc, PhD, FESC; Gerhard-Paul Diller, MD, PhD, FESC; Alexander R. Opatowsky, MD, MPH, MMSc; Michele D'Alto, MD, PhD, FESC; Hong Gu, MD, PhD; George Giannakoulas, MD, PhD; Werner Budts, MD, PhD, FESC; Craig S. Broberg, MD; Gruschen Veldtman, FRCP, MBChB; Lorna Swan, MBChB, FRCP, MD; Maurice Beghetti, MD, FESC; Michael A. Gatzoulis, MA, MD, PhD, FESC, FACC



In patients with complex pulmonary atresia or truncus arteriosus, the **RV does not eject blood into the pulmonary circulation**, and hence it is not directly affected by changes in pulmonary pressure and resistances

Separate detailed assessment of PA pressures and calculation of pulmonary vascular resistance (PVR) in each lung segment is required to fully understand lung pathophysiology and the severity of PH in these patients. This often, however, proves difficult even in expert hands.

Targeted therapy may be beneficial

TABLE 1 Summary of four registries assessing risk scores

	REVEAL [17–19]	Swedish PAH Register [6]	COMPERA [7]	French Pulmonary Hypertension Network [8]
Required variables n	12–14	8	8	4
Patients at baseline n	2716	530	1588	1017
Patients at follow-up n	2529	383	1094	1017
Associated PAH included	Yes	Yes	Yes	No
Definition of low risk	≤6 REVEAL score	<1.5 average score	<1.5 average score	3–4 out of 4 low-risk criteria
1-year mortality by risk group (low/intermediate/high) %	≤2.6/7.0/≥10.7	1.0/7.0/26.0	2.8/9.9/21.2	1.0/NA/13.0–30.0

- Interestingly, the variables with the highest yield in the registries analyses are similar, i.e. FC, 6MWD, NT-proBNP or BNP plasma levels, cardiac index, RAP and SvO₂

Galie et al Eur J Respir 2019
Dardi wt al ESC 2018

VALLERIE V. MCLAUGHLIN

00:10:51




Simplified Risk stratification in PAH



Prognostic Criteria		Low risk variables	Intermediate risk variables	High risk variables
A.	WHO functional class	I, II	III	IV
B.	6MWD	> 440 m	165–440 m	< 165 m
C.	NT-proBNP/BNP plasma levels	BNP < 50 ng/l NTproBNP < 300 ng/ml	BNP 50–300 ng/l NT-proBNP 300–1400 ng/l	BNP > 300 ng/l NT-proBNP > 1400 ng/l
	OR RAP	OR RAP < 8 mmHg	OR RAP 8–14 mmHg	OR RAP > 14 mmHg
D.	CI	CI ≥ 2.5 l/min/m ²	CI 2.0–2.4 l/min/m ²	CI < 2.0 l/min/m ²
	OR SvO ₂	OR SvO ₂ > 65%	OR SvO ₂ 60–65%	OR SvO ₂ < 60%



Burden of Heart Failure in Adults with Congenital Heart Disease





Growing Adult Congenital Heart Disease Population

Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology

Werner Budts^{1*}, Jolien Roos-Hesselink², Tanja Rädle-Hurst³, Andreas Eicken⁴, Theresa A. McDonagh⁵, Ekaterini Lambrinou⁶, Maria G. Crespo-Leiro⁷, Fiona Walker⁸, and Alexandra A. Frogoudaki⁹




Causes and Mechanisms

Causes	Mechanisms
Genetics	Sarcomere structure
CHD-related hemodynamic sequelae	Pressure and/or pressure-volume overload of systemic and/or subpulmonary ventricle, reduced cardiac output
Fibrosis	Hypertrophy, increased filling pressures, surgical scars
Cyanosis	Hypoxia
Impaired myocardial perfusion—ischemia	Congenital coronary artery abnormalities, postsurgical coronary artery abnormalities, demand-supply oxygen mismatch
Arrhythmias	Tachycardia-induced cardiomyopathy, dyssynchrony
Acquired heart disease	Coronary artery disease, diabetes mellitus, arterial hypertension




Exercise Intolerance





Management





Congenital Heart Disease in Adolescents and Adults
Series Editors: Massimo Chessa · Helmut Baumgartner
Andreas Eicken · Alessandro Giamberti

Lorna Swan · Alexandra A. Frogoudaki
Editors

Heart Failure in Adult Congenital Heart Disease

 Springer

